A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Kunz, P. L., Nandoskar, P., Koontz, M., Ji, H., Ford, J. M., Balise, R. R., Kamaya, A., Rubin, D., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY. 2014

View details for DOI 10.1200/jco.2014.32.3_suppl.115

View details for Web of Science ID 000333682100120